Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 May;77(10):1683–1685. doi: 10.1038/bjc.1998.277

Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study.

R T Poon 1, L W Chow 1
PMCID: PMC2150069  PMID: 9635849

Abstract

A double-blind randomized crossover trial was performed to compare the antiemetic efficacy of two 5-HT3 receptor antagonists, granisetron and ondansetron, in Chinese patients receiving adjuvant chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil) for breast cancer. Twenty patients were randomized to receive chemotherapy with either granisetron on day 1 and ondansetron on day 8 of the first cycle followed by the reverse order in the second cycle, or vice versa. The number of vomiting episodes and the severity of nausea in the first 24 h (acute vomiting/nausea) and the following 7 days (delayed vomiting/nausea) were studied. Acute vomiting was completely prevented in 29 (72.5%) cycles with granisetron and 27 (67.5%) cycles with ondansetron, and treatment failure (>5 vomiting episodes) occurred in two (5%) cycles with each agent (P = NS). Acute nausea was completely controlled in 15 (37.5%) cycles with granisetron and 14 (35%) cycles with ondansetron, whereas severe acute nausea occurred in four (10%) cycles with each agent (P = NS). However, complete response for delayed vomiting was observed in only 21 (52.5%) cycles with granisetron and 22 (55%) cycles with ondansetron (P = NS), and delayed nausea was completely controlled in only 11 (27.5%) and ten (25%) cycles respectively (P = NS). In conclusion, both granisetron and ondansetron are effective in controlling acute nausea and vomiting in Chinese patients, with equivalent antiemetic efficacy. Control of delayed nausea and vomiting is less satisfactory.

Full text

PDF
1683

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bloomer J. C., Baldwin S. J., Smith G. J., Ayrton A. D., Clarke S. E., Chenery R. J. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol. 1994 Dec;38(6):557–566. doi: 10.1111/j.1365-2125.1994.tb04397.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bonneterre J., Hecquet B. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomized study. Eur J Cancer. 1994;30A(7):1041–1042. doi: 10.1016/0959-8049(94)90152-x. [DOI] [PubMed] [Google Scholar]
  3. Fischer V., Vickers A. E., Heitz F., Mahadevan S., Baldeck J. P., Minery P., Tynes R. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos. 1994 Mar-Apr;22(2):269–274. [PubMed] [Google Scholar]
  4. Gebbia V., Cannata G., Testa A., Curto G., Valenza R., Cipolla C., Latteri M. A., Gebbia N. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer. 1994 Oct 1;74(7):1945–1952. doi: 10.1002/1097-0142(19941001)74:7<1945::aid-cncr2820740720>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  5. Jantunen I. T., Muhonen T. T., Kataja V. V., Flander M. K., Teerenhovi L. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study. Eur J Cancer. 1993;29A(12):1669–1672. doi: 10.1016/0959-8049(93)90101-k. [DOI] [PubMed] [Google Scholar]
  6. Johansson I., Oscarson M., Yue Q. Y., Bertilsson L., Sjöqvist F., Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994 Sep;46(3):452–459. [PubMed] [Google Scholar]
  7. Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet. 1982 Sep-Oct;7(5):373–400. doi: 10.2165/00003088-198207050-00001. [DOI] [PubMed] [Google Scholar]
  8. Kris M. G., Gralla R. J., Clark R. A., Tyson L. B., O'Connell J. P., Wertheim M. S., Kelsen D. P. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985 Oct;3(10):1379–1384. doi: 10.1200/JCO.1985.3.10.1379. [DOI] [PubMed] [Google Scholar]
  9. Mantovani G., Macciò A., Bianchi A., Curreli L., Ghiani M., Proto E., Santona M. C. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer. 1996 Mar 1;77(5):941–948. [PubMed] [Google Scholar]
  10. Navari R., Gandara D., Hesketh P., Hall S., Mailliard J., Ritter H., Friedman C., Fitts D. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol. 1995 May;13(5):1242–1248. doi: 10.1200/JCO.1995.13.5.1242. [DOI] [PubMed] [Google Scholar]
  11. Noble A., Bremer K., Goedhals L., Cupissol D., Dilly S. G. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group. Eur J Cancer. 1994;30A(8):1083–1088. doi: 10.1016/0959-8049(94)90461-8. [DOI] [PubMed] [Google Scholar]
  12. Relling M. V. Polymorphic drug metabolism. Clin Pharm. 1989 Dec;8(12):852–863. [PubMed] [Google Scholar]
  13. Roila F., Tonato M., Cognetti F., Cortesi E., Favalli G., Marangolo M., Amadori D., Bella M. A., Gramazio V., Donati D. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991 Apr;9(4):675–678. doi: 10.1200/JCO.1991.9.4.675. [DOI] [PubMed] [Google Scholar]
  14. Ruff P., Paska W., Goedhals L., Pouillart P., Rivière A., Vorobiof D., Bloch B., Jones A., Martin C., Brunet R. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology. 1994 Jan-Feb;51(1):113–118. doi: 10.1159/000227321. [DOI] [PubMed] [Google Scholar]
  15. Stewart A., McQuade B., Cronje J. D., Goedhals L., Gudgeon A., Corette L., Froger X., Tubiana-Hulin M., Laplaige P., Roberts J. T. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients. Oncology. 1995 May-Jun;52(3):202–210. doi: 10.1159/000227458. [DOI] [PubMed] [Google Scholar]
  16. Tonato M., Roila F., Del Favero A. Methodology of antiemetic trials: a review. Ann Oncol. 1991 Feb;2(2):107–114. doi: 10.1093/oxfordjournals.annonc.a057871. [DOI] [PubMed] [Google Scholar]
  17. Vetticaden S. J. Polymorphic differences in drug metabolism and response. Methods Find Exp Clin Pharmacol. 1988 Aug;10(8):531–536. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES